Common name
fluoroform
IUPAC name
fluoroform
SMILES
FC(F)F
Common name
fluoroform
IUPAC name
fluoroform
SMILES
FC(F)F
INCHI
InChI=1S/CHF3/c2-1(3)4/h1H
FORMULA
CHF3
Common name
fluoroform
IUPAC name
fluoroform
Molecular weight
70.014
clogP
1.935
clogS
-0.621
Frequency
0.0704
HBond Acceptor
0
HBond Donor
0
Total PolarSurface Area
0
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00637 | Hydroflumethiazide |
|
Antihypertensive Agents; Diuretics; Sodium Chloride Symporter Inhibitors; Cardiovascular System; Thiazides, Plain; Low-Ceiling Diuretics, Thiazides; | Used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. |
| FDBD00663 | Halazepam |
|
Anti-Anxiety Agents; Hypnotics and Sedatives; Benzodiazepines; Neuromuscular Agents; Nervous System; Benzodiazepine Derivatives; Anxiolytics; Psycholeptics; | Used to relieve anxiety, nervousness, and tension associated with anxiety disorders. |
| FDBD00693 | Trifluoperazine |
|
Antipsychotic Agents; Adrenergic alpha-1 Receptor Antagonists; Antiemetics; Dopamine Antagonists; Phenothiazines; Nervous System; Psycholeptics; Phenothiazines With Piperazine Structure; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; | For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation. |
| FDBD00735 | Flupentixol |
|
Antipsychotic Agents; Adrenergic alpha-1 Receptor Antagonists; Dopamine Antagonists; Thioxanthenes; Nervous System; Psycholeptics; Thioxanthene Derivatives; | For use in the treatment of schizophrenia and depression. |
| FDBD00787 | Tipranavir |
|
Anti-HIV Agents; Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors. |
| FDBD00802 | Fulvestrant |
|
Antineoplastic Agents; Antineoplastic Agents, Hormonal; Estrogen Antagonists; Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; Anti-Estrogens; CYP3A4 Inhibitors; Estrogen Receptor Antagonists; | For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. |
| FDBD00866 | Cinacalcet |
|
Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Anti-Parathyroid Agents; Calcium Homeostasis; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Calcimimetic Agents; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma. |
| FDBD00947 | Leflunomide |
|
Antirheumatic Agents; Immunosuppressive Agents; Enzyme Inhibitors; Adjuvants; Antineoplastic and Immunomodulating Agents; Selective Immunosuppressants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; | For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use. |
| FDBD00975 | Dutasteride |
|
Adrenergic alpha-Antagonists; 5-alpha Reductase Inhibitors; Genito Urinary System and Sex Hormones; Drugs Used in Benign Prostatic Hypertrophy; Testosterone-5-Alpha Reductase Inhibitors; Urological Agents; CYP3A4 Inhibitors; | For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for surgery. |
| FDBD00977 | Bicalutamide |
|
Antineoplastic and Immunomodulating Agents; Endocrine Therapy; Hormone Antagonists and Related Agents; Anti-Androgens; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. |
205 ,
21
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 2gh6_ligand_frag_9.mol2 | 2gh6 | 1 | -5.41 | C(F)(F)F | 4 |
| 4m3d_ligand_frag_8.mol2 | 4m3d | 1 | -5.38 | C(F)(F)F | 4 |
| 1ela_ligand_frag_1.mol2 | 1ela | 1 | -5.37 | C(F)(F)F | 4 |
| 1ele_ligand_frag_1.mol2 | 1ele | 1 | -5.37 | C(F)(F)F | 4 |
| 4m3b_ligand_frag_0.mol2 | 4m3b | 1 | -5.37 | FC(F)F | 4 |
| 4m3e_ligand_frag_0.mol2 | 4m3e | 1 | -5.37 | FC(F)F | 4 |
605 ,
61
